We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer is making major changes in the way the company is run in an effort to drive down costs, increase revenue and enhance innovation, Pfizer announced at a meeting of its senior staff.
The success of the top U.S. heart-device manufacturers in 2007 will depend on the specific market forces individual firms are dealing with, analysts say.
The "art and science" of branding -- developing name and image recognition for a particular product and company -- is still in the developmental stages in the device industry, according to Nancy Turett, president of the health division at Edelman, a public relations and strategic communications consulting firm.
An analysis of 84 studies by HHS’ Agency for Healthcare Research and Quality (AHRQ) found no strong evidence that atypical antipsychotics are effective for many of the off-label uses for which they are commonly prescribed.
Republican members of the House and Senate are proposing a federal commission to study entitlement spending, including Medicare and Medicaid, with an eye toward developing ways to lower the costs of these programs.
GlaxoSmithKline (GSK) will undertake a head-to-head study of its candidate to prevent cervical cancer against Merck’s drug Gardasil in an effort to sway the market, GSK said.
Nearly nine in 10 adults (88 percent) in Great Britain are confident about the safety of medicines, according to an independent survey released by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) Dec. 12.
Eli Lilly announced it is stopping construction of an insulin manufacturing plant in Prince William County, Va., because demand is not as high as the company thought when it planned the facility in 2003.